Along with the well-known rewarding effects, activation of nicotinic acetylcholine receptors (nAChRs) can also relieve pain, and some nicotinic agonists have analgesic efficacy similar to opioids. A major target of analgesic drugs is the descending pain modulatory pathway, including the ventrolateral periaqueductal gray (vlPAG) and the rostral ventromedial medulla (RVM). Although activating nAChRs within this circuitry can be analgesic, little is known about the subunit composition and cellular effects of these receptors, particularly within the vlPAG. Using electrophysiology in brain slices from adult male rats, we examined nAChR effects on vlPAG neurons that project to the RVM. We found that 63% of PAG-RVM projection neurons expressed functional nAChRs, which were exclusively of the a7-subtype. Interestingly, the neurons that express a7 nAChRs were largely nonoverlapping with those expressing m-opioid receptors (MOR). As nAChRs are excitatory and MORs are inhibitory, these data suggest distinct roles for these neuronal classes in pain modulation. Along with direct excitation, we also found that presynaptic nAChRs enhanced GABAergic release preferentially onto neurons that lacked a7 nAChRs. In addition, presynaptic nAChRs enhanced glutamatergic inputs onto all PAG-RVM projection neuron classes to a similar extent. In behavioral testing, both systemic and intra-vlPAG administration of the a7 nAChR-selective agonist, PHA-543,613, was antinociceptive in the formalin assay. Furthermore, intra-vlPAG a7 antagonist pretreatment blocked PHA-543,613-induced antinociception via either administration method. Systemic administration of submaximal doses of the a7 agonist and morphine produced additive antinociceptive effects. Together, our findings indicate that the vlPAG is a key site of action for a7 nAChR-mediated antinociception.
Introduction
Activation of supraspinal nicotinic acetylcholine receptors (nAChRs) is analgesic in animal models of both acute and chronic pain. 8, 14, 15, 53 In fact, the nAChR agonist ABT-594 displayed antinociceptive efficacy similar to m-opioid receptor (MOR) agonists, and these effects were attributed to activation of the rostral ventromedial medulla (RVM). 8 In human testing, however, ABT-594 induced adverse side effects that have precluded its clinical use. 66 Examination of another agonist with higher selectivity for the a4b2 nAChR subtype, ABT-894, had limited analgesic efficacy in patients with chronic neuropathic pain.
These observations suggest that other nAChRs may underlie antinociception, and this is also supported by data showing that nicotinic agonists are antinociceptive after deletion or knockdown of a4 and b2 subunits in rodent models. 15, 53 Recent work has explored the analgesic effects of the homomeric a7 nAChR subtype. Systemic administration of a7 nAChR agonists and a7 knockout/knockin studies demonstrate that a7 nAChR activation can be antinociceptive in various pain models. 4, [29] [30] [31] In addition, other studies suggest a supraspinal site of action for these receptors. Intracerebroventricular administration of a7-selective agonists is antinociceptive in acute, inflammatory, and neuropathic pain models, 6, 23, 39, 80 but the neural substrates of these effects are unknown.
Nicotinic receptors are expressed in the ventrolateral periaqueductal gray (vlPAG), 5 which is another component of the pain modulatory pathway that projects to the RVM. 10 Electrical stimulation of the PAG in rats and humans produces analgesia, 24, 83 and RVM lesions block PAG-stimulated antinociception in rats. 10 In addition, nAChR activation in the PAG has antinociceptive effects in vivo, 37 however, the subunit composition of PAG nAChRs and their impact on PAG output to the RVM is unknown. Thus, we investigated the physiology of vlPAG neurons that project to RVM. Previous studies indicate that a subset of vlPAG-RVM projection neurons express MORs. 59 Both MOR and nAChR activation leads to antinociception, yet somatic MOR activation inhibits PAG neurons, 61 whereas somatodendritic nAChRs generally increase neuronal excitability. These distinct effects on neuronal activity suggest a functional segregation of somatic MORs and nAChRs between distinct neuronal subpopulations in vlPAG. Using retrograde labeling methods, we identified vlPAG neurons that project to the RVM in brain tissue slices, and then tested functional expression of opioid and nicotinic receptors in these neurons.
In addition to somatic nAChR expression, we also investigated expression of presynaptic nAChRs on the excitatory and inhibitory inputs to vlPAG neurons, as synaptic modulation is an important role for these receptors in other brain areas. 50, 52, 58, 63 After establishing the functional effects of nAChRs in the vlPAG, we then tested the behavioral relevance of these physiological effects using the formalin assay to examine acute and tonic nociception while modulating a7 nAChR activity.
Methods

Animals
All animal procedures were approved by the Animal Care and Use Committee at the University of Chicago. Adult male Sprague Dawley rats (.8 weeks; Harlan, Indianapolis, IN) were anesthetized with intraperitoneal injections of 100 mg/kg ketamine (Butler Animal Health, Dublin, OH) and 10 mg/kg xylazine (Lloyd Labs, Shenandoah, IA), and stereotaxically injected with 2 mL of fluosphere microspheres (580/605; Life Technology, Carlsbad, CA) into the RVM (A/P:210.5, L: 10.1, D/V: 210.1 mm; Paxinos & Watson, 2007 , Kopf Instr, Tujunga, CA). The animals were allowed to recover for a minimum of 72 hours before anatomic or electrophysiological investigation.
Preparation and visualization of brain slices
Rats were anesthetized with isoflurane (Baxter, Deerfield, IL) and rapidly decapitated. The brains were dissected in ice-cold sucrose artificial cerebrospinal fluid (aCSF) containing: 200 mM sucrose, 2.5 mM KCl, 1 mM MgCl 2 , 2.5 mM CaCl 2 , 20 mM glucose, 1 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 10 mM ascorbic acid, which was bubbled with 95% O 2 to 5% CO 2 during dissection and slicing. Coronal slices (250-300 mm thick) including the PAG were prepared on a vibratome (Leica) and transferred to the aCSF solution (32˚C) containing: 125 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 2.5 mM CaCl 2 , 20 mM glucose, 1 mM NaH 2 PO 4 , 1 mM 25 NaHCO 3 , 1 mM ascorbic acid, which was bubbled with 95% O 2 to 5% CO 2 . For recording, the slices were transferred to a chamber continuously perfused with aCSF without ascorbic acid and bubbled with 95% O 2 to 5% CO 2 . Whole cell patch-clamp recordings were achieved with microelectrodes (3-6 MV) pulled on a Flaming/Brown micropipette puller (model P-97; Sutter Instrument, Novato, CA). Recording electrodes were filled with potassium gluconate internal solution: 154 mM K-gluconate, 1 mM KCl, 1 mM EGTA, 10 mM HEPES, 10 mM glucose, 5 mM ATP, 0.1 mM GTP, pH 7.4 with KOH). All physiology experiments were performed at room temperature on back-labeled neurons in the ventrolateral region of the PAG. Data were acquired with either a Multiclamp 700A or an Axopatch 200B amplifier and pCLAMP 8 software (Molecular Devices). Retrogradely labeled neurons were visualized under fluorescence illumination (Cy3). Electrodes were guided to the neurons using combined fluorescence and bright field illumination.
To assess somatic nAChR and m-OR expression, acetylcholine (ACh) was applied focally using glass pipettes that were identical to those used as patch electrodes, with pressure controlled by a Picospritzer II (300-ms duration; General Valve, Fairfield, NJ). Pipettes were positioned less than 30 mm from the recorded cell immediately prior to ACh application, and then raised above the slice between tests. The pharmacology of nAChR subtypes was determined with bath application of a7 nAChR antagonists, including: methyllycaconitine (10 nM, Abcam) or a-bungarotoxin (50 nM, Tocris). External aCSF included atropine (1 mM) to block muscarinic ACh receptors. After nAChR subtype assessment, a MOR agonist, endomorphin-1 (EM-1; 1 mM), or [D-Ala, 2 N-MePhe, 4 Gly-ol]-enkephalin (DAMGO; 1 mM) was applied to the slice via bath perfusion.
For testing synaptic modulation by nAChRs, excitatory or inhibitory postsynaptic currents (EPSCs, IPSCs) were isolated pharmacologically. Miniature EPSCs (mEPSCs) were recorded with bicuculline (10 mM, Abcam) to block GABA A receptors, and TTX (1 mM, Abcam) to block voltage-gated Na channels, whereas mIPSCs were recorded with 6,7-dinitroquinoxaline-2,3-dione (DNQX; 10 mM, Abcam) to block AMPA receptor-mediated currents and TTX (1 mM) to block voltage-gated Na 1 channels. "Spontaneous" excitatory or inhibitory transmission was monitored without TTX in the aCSF. For the IPSC recordings an internal solution with a higher chloride concentration was used: 70 mM Kgluconate, 70 mM KCl, 1 mM EGTA, 10 mM HEPES, 10 mM glucose, 15 mM sucrose, 5 mM ATP, and 0.25 mM GTP with pH 5 7.4. All measurements of postsynaptic currents were performed in a voltage clamp with a holding potential of 270 mV. Data were only included from recordings with series resistance ,30 MV, and where input resistance or series resistance varied ,25%.
Formalin assay
Adult male Sprague Dawley rats (.8 week old; 225-250 g) were pair-housed on a reverse dark-light cycle (9 AM-9 PM). Rats were acclimatized to the colony room for 1 week after arrival. Water and standard rat chow were available ad libitum. After acclimatization, guide cannulae (Plastics One) were implanted into the vlPAG at 30˚; A/P: 27.6, L: 13.0, D/V: 25.0 mm. 62 After surgery, the rats were singly housed and allowed to recover for 6 days. During recovery from surgery, the animals were habituated to experimenter handling, the drug microinjection procedure, and the test apparatus to limit stress-induced increases in corticosterone. 25 On test day, the rats received drug injections outlined below followed by the formalin test. Formaldehyde (37%, Fisher Scientific) was diluted to formalin (1.5%, 50 mL) and injected into the intraplantar surface of the left hindpaw. After formalin injection, the rats were placed in the formalin box and nocifensive responses were monitored for 60 minutes. Testing occurred during the early morning hours of the reverse dark cycle (ie, within the first 6 hours of the dark phase of the day).
In vivo drug administration
For focal drug administration, a 1 mL Hamilton syringe was used to inject 0.3 mL over a period of 45 seconds to limit tissue damage. On formalin test day, the rats received an intra-vlPAG infusion of either the a7 nAChR agonist, PHA-543,613 (0.3 or 3 nmol), the a7 nAChR positive allosteric modulator, PNU-120,596 (0.009, 0.09, or 0.9 nmol), the MOR agonist DAMGO (1.9 nmol) or vehicle (0.5% DMSO, 10% Kolliphor HS 15 in sterile saline). PNU-120,596 and PHA-543,613 concentrations were determined empirically in pilot testing, as this is the first study conducting intra-vlPAG injections of these drugs. DAMGO dose and pretreatment times were based upon Meyer et al. 54 In the a7 antagonist 1 PHA-543,613 studies, methyllycaconitine (MLA) (90 pmol) or aBGT (1.5 pmol), were focally administered into the vlPAG 10 or 30 minutes prior to formalin injection, respectively, to allow for diffusion and binding to the receptors. Methyllycaconitine concentrations and pretreatment times were based upon previous studies, 68, 74 and the dose and pretreatment time of aBGT was based on electrophysiology studies showing blockade of functional a7 responses. 22, 34 The intra-vlPAG injection of PHA-543,613 was administered 5 minutes prior to the formalin injection. When MLA or aBGT was administered without PHA-543,613, the rats received a focal vehicle injection 5 minutes prior to the formalin injection. For systemic drug administration, PHA-543,613 (0.2-10 mg/kg, s.c.) and/or morphine (0.067-4 mg/kg, s.c) was then administered 15 and 20 minutes before the formalin injection, respectively. To assess the role of PAG a7 nAChRs following systemic agonist administration either vehicle or aBGT (1.5 pmol) was administered into the vlPAG 30 minutes prior to the formalin injection.
Drugs
All reagents and chemicals were obtained from Sigma (St. Louis, MO) unless otherwise specified.
Histology and immunohistochemistry
Tissue preparation for histology involved isoflurane anesthesia followed by perfusion with 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA) in 0.2 M phosphate buffer. Brains were removed and immersed in fixative for 2 hours and then cryoprotected in 30% sucrose for 72 hours. Coronal sections (35 mm thick) were cut with a cryostat including the PAG. For immunocytochemistry, slices were washed, blocked with normal goat serum, permeabilized with 1% Triton X, and then exposed to a solution containing a tryptophan hydroxylase (TPH) antibody (1:400) (Chemicon, Temecula, CA), followed by an Alexa Fluor 488-conjugated secondary antibody (1:50) (Invitrogen). Control experiments were conducted with secondary antibody alone, which did not yield cellular staining at this dilution. Images were obtained with an Olympus DSU confocal microscope.
After conducting physiology experiments, dye localization was examined in the RVM of each rat under a fluorescent microscope. If the majority of dye was found outside the RVM, those rats were excluded from the dataset. After completion of the formalin assay, placement of the drug injection cannulae was determined by focally injecting each animal with 0.6 mL of fluorescent microspheres (Life Technology) prior to sacrifice. Animals with dye injection entirely outside the boundaries of vlPAG were excluded from the dataset.
Data analysis and statistics
ACh-induced currents were differentiated from baseline noise by thresholding to $10 3 the standard deviation of the baseline noise. This stringent criterion ensured that we did not misidentify presynaptic nAChR-mediated enhanced synaptic activity. MORmediated somatic responses were defined as EM-1 induced outward currents $4 3 root mean square (RMS) noise. The response amplitude was calculated as the mean change in holding current during a 1 minute window at the end of the EM-1 application, relative to pre-drug baseline.
EPSC and IPSC data were analyzed with Mini-Analysis (Synaptosoft, Decatur, GA). Events were distinguished from noise with amplitude, rise time and area thresholds: .4 3 RMS noise, ,1 milliseconds rise time. Determination of "responsive" cells involved comparing the baseline frequency for 60 seconds before nicotine application with a 60 seconds window beginning 30 seconds after nicotine application. Unpaired t test was then used to identify significant frequency differences between baseline and nicotine application periods (P , 0.05). All results are expressed as mean 6 SEM. Graphs were produced with Prism 6 (Graphpad Software). Fisher's exact test was used to compare response prevalence between different test populations.
Formalin-induced nociceptive responses for injected paw were scored using a weighted scale (0-3). 0: Paw flat on the floor surface; 1: Paw curled but still in contact with the floor; 2: Paw lifted off of the floor; 3: Rat licking, shaking, or biting paw. JWatcher (1.0) software was used for data collection and analysis of duration and frequency of nocifensive responses. Nociceptive mean scores per 5 minutes bins were calculated with the following formula:
Where T 5 duration of nocifensive response. 26 Differences in nociceptive scores were analyzed with two-way repeated measures analysis of variance (RM ANOVA) and post-hoc multiple comparison tests. One-way ANOVA was used to compare phase II nociceptive duration.
Results
Functional a7 nAChR expression in vlPAG-RVM projection neurons
PAG neurons that project to the RVM were identified in brain slice recordings by retrograde labeling with fluorescent microspheres stereotaxically injected into the RVM. Labeled vlPAG-RVM projection neurons were visible under fluorescence illumination (Fig. 1A) . Dye injection sites were confirmed prior to recording and control injections dorsal to the RVM did not result in backlabeling of PAG neurons. Caudal vlPAG projections to RVM have been implicated in the modulation of nociceptive signaling, 2,12,32 which led us to focus on this region. Consistent with previous reports showing a low prevalence of serotonin among vlPAG-RVM projection neurons, 12,81 our immunohistochemistry investigation found no backlabeled cells in the vlPAG that were positive for TPH (n 5 77; Fig. 1B ).
Whole cell recording was performed on back-labeled vlPAG-RVM projection neurons, and nAChR expression was tested with focal application of acetylcholine (ACh, 3 mM) in the presence of atropine (1 mM), to inhibit muscarinic receptors (Fig. 1C) . ACh induced inward currents in 49 of 78 recorded cells with mean current amplitude of 165 6 19.1 pA (Fig. 1C, F) . The rapid activation and desensitization kinetics of these responses suggested the involvement of a7 nAChRs. To confirm this, we tested a selective a7 agonist, PHA-543,613, which induced inward currents with a similar prevalence to ACh (8/16 neurons tested; Fig. 1D , F). To further establish nAChR subtype, after recording baseline ACh responses, slices were perfused with the a7 nAChR selective antagonist MLA; 10 nM, and tested again for ACh responses. Methyllycaconitine completely blocked the responses in all cells tested (n 5 15; Fig. 1E , F). As MLA can inhibit non-a7 nAChR subtypes, 55 we also tested the effects of a more selective a7 antagonist, a-bungarotoxin (aBGT). The slow on-rate of aBGT binding precluded the within-cell testing design used for MLA, so we pretreated the vlPAG slices with aBGT (50 nM) for .15 minutes, prior to testing ACh responses. Under these conditions we saw no ACh-induced currents in 9 cells tested ( Fig. 1F ; P 5 0.0003 relative to control by Fisher's exact test).
PNU-120,596 inhibits a7 desensitization and prolongs ACh-induced currents
Agonist application time can affect response kinetics, as drug removal and unbinding can contribute to current decay rates. To demonstrate that the rapid decay of our ACh-induced inward currents is due to receptor desensitization, we compared responses to our test ACh applications (300 ms) and a longer, 2-seconds application. The ACh current kinetics were identical under these conditions (Fig. 1E) , illustrating the rapid desensitization that is a hallmark of a7 nAChRs. The positive allosteric modulator of a7 nAChRs, PNU-120,596, inhibits receptor desensitization and prolongs agonist-induced electrophysiological and behavioral effects. 38 Following the recording of control responses to focal application of ACh (3 mM; Fig. 1G ), slices were treated with PNU-120,596 (20 mM) for 15 minutes. Reapplication of ACh resulted in a markedly prolonged response duration (n 5 3; Fig. 1H ). Overall, these pharmacological data support the idea that a7 is the predominant nAChR subtype in vlPAG-RVM projection neurons.
Segregation of functional nAChR vs MOR expression in vlPAG-RVM neurons
The PAG is a mediator of opioid analgesia, 43, 54, 78 and MORs are expressed by vlPAG-RVM projection neurons. 59 As nAChR s and MORs have opposing effects on excitability, we hypothesized nonoverlapping distribution of these receptors among vlPAG projection neurons. To test MOR responses, the selective agonist endomorphin-1 (EM-1; 1 mM) was bath applied to 37 vlPAG-RVM projection neurons after testing for functional nAChR expression (Fig. 2 insets) . A subset of neurons displayed strong somatic ACh responses with little or no response to EM-1 bath application (n 5 11, Fig. 2 ). Similarly, a separate subset of neurons showed a hyperpolarizing current response to EM-1, but no ACh-induced current (n 5 10; Fig. 2) . A minority of neurons responded to both agonists or neither (n 5 7, 9 respectively, Fig. 2 ). Spearman correlation test showed a negative relationship between peak responses to ACh and EM-1 in each neuron (r 5 0.461, P 5 0.0135). Thus, the majority of vlPAG-RVM projection neurons displayed nonoverlapping responses to either nAChR or MOR agonists, suggesting that these vlPAG projection neurons have differing roles in nociceptive modulation.
Nicotinic modulation of synaptic transmission onto vlPAG-RVM projection neurons
In many areas of the CNS, presynaptic nAChRs can enhance the excitability of neurons by increasing glutamate release probability. 3, 33, 36, [50] [51] [52] 63 In addition to effects of somatodendritic nAChRs, modulation of excitatory/inhibitory drive onto vlPAG projection neurons by presynaptic nAChRs could contribute to analgesia. To assess this possibility in vlPAG-RVM-projection neurons, nicotine (1 mM) was bath applied in the presence of tetrodotoxin (TTX; 1 mM) and bicuculline (10 mM) to isolate miniature excitatory postsynaptic currents (mEPSCs). Nicotine bath application increased mEPSC frequency in both a7-expressing and a7-lacking vlPAG-RVM-projection neurons with no effect on amplitude, which is classically interpreted as presynaptic modulation (Fig. 3A-D) . The prevalence and magnitude of nicotine-induced mEPSC increase in frequency was similar in both a7-expressing and a7-lacking neurons (Fig. 3B, C) . As nAChRs can modulate presynaptic function via expression in preterminal regions of the neuron, 47 we also tested nicotinic modulation of spontaneous EPSCs (sEPSCs), by omitting TTX from the external solution ( Fig. 3B-D) . Although the sEPSC frequency enhancement by nicotine was larger in a7-lacking neurons, the difference was not statistically significant (Fig. 3C) . To test the pharmacology of presynaptic nAChRs, slices were pretreated with MLA (10 nM), and the effect of nicotine (1 mM) was tested on mEPSC frequency. In the presence of MLA, nicotine enhanced mEPSC frequency in 3 of 11 vlPAG neurons (data not shown), which is similar to the prevalence seen with nicotine alone, suggesting that non-a7 nAChR subtypes are expressed on glutamatergic afferents to vlPAG neurons.
The output of the PAG projections to the RVM relies on the balance of inhibitory and excitatory synaptic drive. Presynaptic nAChRs modulate inhibitory synaptic transmission in acutely dissociated PAG neurons. 58 To test whether this extends to vlPAG-RVM projection neurons, nicotine (1 mM) was bath applied in the presence of 6,7-Dinitroquinoxaline-2,3-dione (DNQX; 10 mM) to isolate GABAergic IPSCs. Nicotine enhanced both miniature and spontaneous IPSC frequency in these neurons (Fig. 3E-H) , with a larger proportion of a7-lacking than a7-expressing neurons displaying this effect, particularly for sIPSC frequency ( Fig. 3F ; P , 0.05 by Fisher's exact test). The magnitude of nicotine-induced increase in IPSC frequency did not differ between a7-expressing and a7-lacking neurons (Fig. 3G) . Similar to our glutamatergic findings, nicotine had no effect on IPSC amplitude (Fig. 3H) . Because of the lower prevalence of a7-expressing neurons that showed a nicotineinduced enhancement of IPSC frequency, we explored nAChR pharmacology on afferents to a7-lacking neurons. Following pretreatment with MLA (10 nM; .15 minutes), nicotine enhanced sIPSC frequency in 3/7 neurons (data not shown), supporting the idea that the presynaptic nAChRs on GABAergic inputs to vlPAG are not the a7 subtype.
Overall, the synaptic modulation experiments argue that presynaptic nAChRs increase both excitatory and inhibitory drive onto vlPAG neurons. We observed a higher proportion of a7-lacking vlPAG neurons that showed enhanced inhibitory drive, which may contribute to antinociceptive effects of cholinergic signaling via presynaptic mechanisms. however, the site of action of this treatment is unknown. We tested whether selective activation of a7 nAChRs within vlPAG could mediate antinociception in the formalin assay. Formalin injection under the plantar skin of the hind paw produces distinct acute (phase I, 0-5 minutes) and tonic (phase II, 15-60 minutes) nociceptive periods. 9 More importantly, the tonic phase is reported to involve central sensitization, a mechanism implicated in chronic pain. 19, 69 Guide cannulae were surgically implanted for drug delivery into the vlPAG, and rats were allowed to recover in their home cage (Fig. 4A) . On test day, rats received intra-vlPAG injection of either vehicle, an a7 agonist PHA-543,613 (3 nmol), an a7-positive allosteric modulator PNU-120,596 (0.9 nmol), or the MOR agonist DAMGO (1.9 nmol), as positive control. Vehicle, PNU-120,596, and DAMGO were focally administered into the vlPAG 10 minutes before intraplantar formalin injection, and PHA-543,613 was focally administered 5 minutes before formalin. Consistent with previous reports that implicated vlPAG in MOR-mediated analgesia, 49 focal infusion of DAMGO into the vlPAG resulted in a significant decrease in nocifensive responses during both phase I and phase II of the formalin test (Fig. 4A, B) . Interestingly, although intra-vlPAG administration of PHA-543,613 had no effect on phase I responses, it produced robust, dose-dependent antinociception throughout phase II, which was similar in magnitude to the effects of DAMGO (Fig. 4A-C) . To test the specificity of the vlPAG in the effects of PHA-543,613, a subset of animals received infusions lateral to the vlPAG. As shown in Figure 4D , the duration of nociceptive behaviors during phase II were not affected by lateral infusions of PHA-543,613, supporting the idea that activation of a7 nAChRs within the vlPAG underlies the observed antinociceptive effects. The nociceptive profile following intra-vlPAG infusion of the positive allosteric modulator, PNU-120,596 (0.9 nmol) was similar to vehicle until 40 minutes, and thereafter nociceptive responses decreased sharply, suggesting that PNU-120,596 enhances the effect of cholinergic transmission at these later time points to modulate nociceptive signaling (Fig. 4A, B, E) . Comparison of the time course of nociceptive behaviors during phase II revealed that all 3 drug treatment groups showed substantial reduction in time spent expressing those behaviors relative to vehicle-injected animals (two-way Repeated Measures ANOVA; drug: F(3,33) 5 18.32; P , 0.0001; Fig 4A) . Comparing the overall duration of nociceptive behaviors during phase II showed that all 3 drugs produced antinociception relative to vehicle (one-way ANOVA: F(3,33) 5 20.82; P , 0.0001 for PHA-543,613 and P , 0.01 for PNU120596; Fig 4B) . Furthermore, for PHA-543,613 was only antinociceptive at the 3 nmol dose (one-way Repeated Measures ANOVA; F(5,36) 5 7.904, P , 0.0001, Fig 4C) . The concentration-dependence of PNU-120,596 is illustrated in Figure 4E with a significant effect only seen with the 9 nmol concentration (P , 0.01). While phase II nociceptive mean scores and time course were similar between PHA-543,613 and DAMGO-treated rats, MOR activation produced substantially less licking behavior. Coupled with the difference in antinociception during phase I, these findings suggest that a7 nAChRs and MORs are part of separate nociceptive modulatory circuits within the vlPAG.
After each experiment, fluorescent dye was injected to confirm the position of the drug infusion cannulae. Figure 4F illustrates cannula placement for the animals included in the analysis of drug effects. Animals were excluded if the dye was entirely outside the vlPAG.
Focal pretreatment of a7 nAChR antagonists block a7 agonist antinociception
Focal PHA-543,613-induced antinociception suggested that activation of vlPAG a7 nAChRs leads to antinociception. To further explore this idea, we focally injected a7 nAChR antagonists into the vlPAG prior to the a7 nAChR agonist. IntravlPAG injection of aBGT (1.5 pmol) or MLA (90 pmol) occurred 30 or 10 minutes before formalin administration, respectively. Then PHA-543,613 was injected 5 minutes before the formalin injection. Administration of MLA or aBGT into the vlPAG completely blocked a7 nAChR agonist-induced antinociception during phase II (two-way RM ANOVA; drug: F(5,38) 5 7.71; P , 0.001; Fig. 5A, B) . Together, these data support the idea that activation of a7 nAChRs in the vlPAG induces antinociception in a tonic pain model.
Systemic PHA-543,613 antinociception is dependent on vlPAG a7 nAChR activation
Previous studies have reported antinociceptive effects of systemic administration of PHA-543,613, 29 but the sites of action of those effects were not investigated. We tested subcutaneous injections of a range of PHA-543,613 concentrations (0.2, 1, 2, 4, or 10 mg/kg, s.c.) and saw a concentration-dependent effect on phase II nociceptive responses in the formalin assay (Fig. 6A, B) . For clarity, in Figure 6A , we only included vehicle, 4 mg/kg PHA-543,613, alone and with aBGT pretreatment. At 4 mg/kg, PHA-543,613 substantially decreased nociceptive behaviors during phase II ( Fig. 6B ; one-way ANOVA: F(6,31) 5 4.65; P , 0.001). The higher concentration (10 mg/kg) had no antinociceptive effect, presumably due to a predominance of receptor desensitization (Fig. 6B) . To explore the contribution of vlPAG to this antinociceptive effect, aBGT was focally injected into the vlPAG 30 minutes before formalin injection. The rats received a systemic injection of PHA-543,613 (4 mg/kg, s.c.) 15 minutes after the aBGT injection. The animals were then tested in the formalin assay 15 minutes later. The antinociceptive effect of systemic PHA-543,613 was completely blocked by intra-vlPAG injection of aBGT (P , 0.01; Fig. 6B ). These findings strongly suggest that a7 nAChRs in the vlPAG are a key site for a7 nAChRmediated antinociception.
Co-administration of low-dose a7 and MOR agonists leads to enhanced vlPAG-dependent antinociception
Over the past decade, long-term opioid therapy as a chronic pain treatment has become increasingly prevalent; 16, 70 however, many patients eventually stop opioid treatment due to lack of efficacy, which is suggestive of opioid analgesic tolerance. 45 One way to address this problem is to use combination pharmacotherapy, where 2 drugs are coadministered to achieve pain relief. 35 The goal is to relieve pain with lower opioid concentrations, to help delay the development of tolerance. Therefore, we tested antinociceptive effects of combining systemic administration of an a7 agonist with morphine. First, we tested the antinociceptive effects of a range of morphine doses in the formalin assay (Fig. 7A-B) . Systemic morphine injections were preceded by a focal vehicle injection 30 minutes before the formalin administration. We observed a concentrationdependent antinociceptive effect, with complete block of nocifensive responses with 4 mg/kg morphine, which is similar to previous reports 1 (two-way RM ANOVA; drug: F(3,17) 5 14.25, P , 0.0001; Fig. 7A, B) . For the drug combination studies, we used the intermediate dose of 0.67 mg/kg morphine that produced weak antinociceptive effects. After focal vehicle pretreatment, we administered this dose subcutaneously in combination with 1, 2, or 4 mg/kg PHA-543,613 (Fig. 7C-D) . This drug combination enhanced antinociception of the 2 mg/kg and 4 mg/ kg doses of PHA-543,613, with the latter producing complete block of phase II nocifensive responses, similar to that seen with the 4 mg/kg dose of morphine ( Fig. 7D; P , 0.0001) . Interestingly, intra-vlPAG aBGT pretreatment blocked the combined antinociceptive effects of morphine 1 PHA-543,613 (2 mg/kg; one-way ANOVA: F(4,24) 5 4.36, P , 0.01; Fig. 7C ). These findings support the idea that a7 nAChRs within the vlPAG are necessary for the antinociceptive effects of combining a7 and MOR agonists.
This effect of aBGT on the drug combination led us to test whether a7 nAChR activity in the vlPAG could be contributing to the antinociceptive effects of morphine alone. Thus, we administered aBGT into the vlPAG prior to a systemic injection of a 2 mg/kg morphine dose, which was the lowest dose tested that produced significant antinociceptive effects under control conditions (Fig. 2B) . Under these conditions, aBGT did not alter the antinociceptive effects of morphine (mean phase II nocifensive behaviors: 87 6 85 seconds vs 107 6 89 seconds for vehicle vs aBGT, respectively; one-way ANOVA: F(2,12) 5 0.236, P 5 0.89), suggesting that its block of the drug combination was solely through its effects on the antinociceptive effects of a7 nAChRs.
Discussion
Although opioids are the most commonly used treatments for chronic pain, their use is associated with adverse events, including nausea, constipation, depression, abuse liability and tolerance or loss of efficacy. 7, 77 Thus, exploring alternative analgesic targets is an ongoing goal in pain research. Nicotinic agonists have shown promise as alternatives to opioid drugs, but adverse side effects have confounded their advancement to the clinic. Activators or positive allosteric modulators of a7 nAChRs may have a less severe side effect profile, and our data suggest that these receptors may be efficacious in the treatment of tonic pain conditions. We found a7 nAChR expression by a subset of vlPAG neurons that project to the RVM, which are important components of descending pain control circuitry. 24, 40, 54, 60, 83 A large fraction of vlPAG-RVM projection neurons express functional a7 nAChRs (63%). Further testing revealed a negative correlation between the responses to ACh and a MOR agonist in the same neurons. Although somatodendritic MOR expression has been demonstrated previously in vlPAG, 17, 59 this is the first report of functional a7 nAChR expression in a subset of vlPAG-RVM projection neurons that is largely nonoverlapping with those expressing MORs.
Presynaptic nAChRs enhance the release of GABA and glutamate in many CNS regions. 51, 52, 63 We explored this phenomenon in vlPAG-RVM projection neurons and found that presynaptic nAChRs enhance glutamatergic transmission onto both a7-expressing and a7-lacking neurons. Acting on presynaptic nAChRs, nicotine enhances GABAergic transmission onto a substantially larger proportion of a7-lacking neurons than a7-expressing neurons in the vlPAG. Thus, not only could endogenous ACh produce analgesia via somatodendritic a7 nAChR activation, but ACh could also suppress activity of MOR-expressing vlPAG-RVM projections. Interestingly, nicotinic modulation of GABA and glutamate release in vlPAG was not blocked by the a7 antagonist, MLA. Thus, a7 nAChRmediated analgesia likely does not involve presynaptic mechanisms in the vlPAG, however, presynaptic nAChRs may contribute to modulation of vlPAG excitability via endogenous ACh transmission.
Our behavioral data support an important role for vlPAG a7 nAChRs in descending pain control. Either focal or systemic administration of an a7 agonist is antinociceptive during the tonic, but not the acute phase of the formalin test. The a7 antinociceptive effects via either focal or systemic agonist administration can be inhibited by intra-vlPAG infusion of a7 antagonists, supporting a key role of these receptors in antinociception. Systemic administration of a combination of a submaximal morphine dose with an a7 agonist resulted in an additive effect in the reduction of nociceptive responses. These data are consistent with independent cellular substrates for these drugs that lead to a common behavioral endpoint. The additive effects of these drugs may lead to new treatment strategies for limiting opioid tolerance.
Our findings suggest a model of a7 nAChR-mediated analgesia in the vlPAG, similar to the ON/OFF cell categorization in the RVM. 28 In this model, 2 subclasses of PAG projection neurons have opposing effects on nociceptive transmission, where a7-expressing neurons are antinociceptive, and MOR-expressing neurons are pronociceptive (Fig. 8) . The downstream circuitry that underlies the opposing physiological effects of the PAG remains unknown. 56, 59 Projections from vlPAG to RVM include both GABAergic and glutamatergic cell types. 57 We did not find evidence of serotonin expression by vlPAG-RVM projection neurons. Future studies will determine the relevant neurotransmitters expressed by the distinct vlPAG cell populations.
In our testing of somatic responses to the MOR agonist EM1, we found a higher response prevalence than previously reported for RVM-projecting vlPAG neurons (50% in our study vs 14% reported previously). 59 It is unlikely that EM1 responses in our studies were confounded by changes in synaptic transmission, as MOR agonists decrease, rather than increase GABA and glutamate release.
18,61 A more likely explanation for the differences is that our recordings were exclusively from adult animals, whereas Osborne et al. (1996) used juvenile rats, and there are reports of developmental differences in receptor expression in the PAG. 64 In agreement with our data, a recent study reported MOR immunoreactivity in roughly 50% of PAG-RVM-projection neurons. 21 Although presynaptic opioid disinhibition of PAG output neurons is a key mechanism for analgesia, 18, 46, 76 it is likely that somatic MORs also contribute to the analgesic effects of opioid drugs. While there is evidence for the involvement of PAG nAChRs in descending analgesia, 37 the receptor subtypes involved and their influence on the PAG-RVM output have not been investigated previously. Our evidence for antinociception mediated by a7 nAChRs in the PAG contrasts with the RVM, where the a4b2 subtype is predominant. Although antinociceptive effects of systemic administration of a7 nAChR agonists have been attributed to peripheral and spinal a7 expression, 73 recent evidence suggests a supraspinal site of action. I.C.V. administration of a7-selective agonists produces analgesia in acute and chronic pain models and these effects were blocked by central administration of a7-antagonists. 6, 23, 39, 80 While peripheral a7 receptors may contribute to antinociception, our data show that the vlPAG is an important site for a7 nAChR-induced antinociception in a tonic pain model.
An interesting aspect of a7 nAChR activation-induced antinociception is the persistence of the effects in the formalin assay. 29 After agonist binding, the a7 nAChR desensitizes within seconds, 22 but this loss of function is not a likely mediator of antinociception, as administration of the antagonists MLA and aBGT had no effect on the magnitude or duration of the nociceptive responses in our tests. The persistence of the behavioral effects after a single infusion suggests that a7 nAChR activation may induce neural plasticity in the vlPAG. Indeed, a7 agonists can induce phosphorylation of extracellular-signal regulated kinase, 13 which has been linked to Ca 21 -mediated synaptic plasticity. 72 Nociceptive states have been associated with changes in glutamatergic transmission, particularly in the PAG. 41 Formalin injection enhances NR2B subunit expression in the anterior cingulate cortex, 48 but its effect in vlPAG is unknown. Retrograde tracing studies indicate dorsal horn neurons project to the vlPAG, 42, 82 and a subset of these neurons are glutamatergic. 82 A key feature of the formalin assay is a sustained increase in dorsal horn excitability, 20 which may result in persistent glutamate release to vlPAG neurons. Enhanced glutamatergic drive, in combination with a7 nAChR activation, can induce LTP in hippocampus, 44 and similar mechanisms may occur in the vlPAG.
The contribution of endogenous cholinergic signaling to antinociception is also intriguing. Systemic administration of the a7 positive allosteric modulator, PNU-120,596 reduces nocifensive responses in the formalin assay, 29 and we found effects only at later timepoints. These data suggest that PNU-120,596 may promote a7 nAChR-dependent plasticity mechanisms, on a longer timescale. The vlPAG is innervated by several cholinergic nuclei, including lateral hypothalamus, laterodorsal and pedunculopontine tegmental nuclei. 11, 75, 79 The abundant expression of acetylcholinesterase in the vlPAG is consistent with strong cholinergic input. 67 At the synapse, acetylcholine is quickly hydrolyzed to acetate and choline; and choline is a low-affinity a7 nAChR agonist. 27, 38 Physiological concentrations of choline (10 mM) can induce activation of a7 nAChRs in the presence of PNU-120,596. 38 It is possible that PNU-120,596 promotes cholineinduced a7 nAChR activation, which may contribute to neural plasticity in the vlPAG. Alternatively, there could be increased ACh tone in vlPAG at later time points in the formalin assay, and PNU-120,596 would certainly enhance the effects of endogenous ACh.
Tolerance to the analgesic effect of opioid drugs is a major clinical problem. Combining efficacious a7 drugs with opioids could result in substantial analgesia with lower opioid doses, which could delay the onset of tolerance and limit opioid use. We found that coadministration a7 and MOR agonists at intermediate doses lead to an additive reduction in pain-like behaviors. This is consistent with independent cellular mechanisms of these 2 receptor classes, as shown in our physiological demonstration of receptor expression in different vlPAG-RVM projection neurons. It is unlikely that this additive effect is due to interaction of morphine with nAChRs, or vice versa, as the morphine concentrations that interact with nAChRs are at least 2 orders of magnitude higher than the estimated brain concentrations in our studies. 71 Our finding that intra-vlPAG administration of aBGT blocked antinociception by the morphine/a7 agonist drug combination initially suggested a role of a7 nAChR-mediated cholinergic transmission in the antinociceptive effects of morphine. However, subsequent testing indicated that aBGT in the vlPAG had no effect on the analgesic effects of an effective dose of morphine alone. Again, these data are consistent with independent cellular effects of MOR and nAChRs in this system, with limited modulation of cholinergic output occurring during MOR antinociception.
In conclusion, our demonstration of a7 nAChR expression by a subset of PAG-RVM-projection neurons provides insights into the physiology of these neurons. a7 agonist-induced antinociception in the formalin assay, and its blockade with antagonist administration into the vlPAG support the idea that this is a key site for nicotinic analgesia. Identifying novel treatments for pain will require further investigation of the physiology of the vlPAG, particularly in chronic treatment models and in the context of opioid tolerance. Figure 8 . Model of a7 nAChR-mediated analgesia in the vlPAG. Our experiments show that vlPAG a7 activation produces robust antinociception principally through the activation of somatic receptors on a subset of neurons within that nucleus. Our behavioral data support the idea that pain inhibitory neurons in the vlPAG suppress ascending nociceptive signaling through connections in the RVM to modulate excitability in the spinal cord dorsal horn. MOR agonist application inhibits a separate group of vlPAG projection neurons that facilitate nociceptive signaling.
